Cytotoxic, apoptotic and molecular effects of fucoidan as single agent and in combination with trastuzumab and docetaxel in HER2(+) breast cancer cells

被引：0
|
作者：
Aygunes, Duygu
Sezgin, Canfeza
Uslu, Ruchan
Kosova, Buket
机构：
[1] Ege Univ, Sch Med, Dept Med Biol, Izmir, Turkey
[2] Ege Univ, Sch Med, Tulay Aktas Oncol Hosp, Izmir, Turkey
[3] Ege Univ, Sch Med, Izmir, Turkey
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13520
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
    Meng Zhao
    Xueliang Pan
    Rachel Layman
    Maryam B. Lustberg
    Ewa Mrozek
    Erin R. Macrae
    Robert Wesolowski
    Sarah Carothers
    Shannon Puhalla
    Charles L. Shapiro
    Bhuvaneswari Ramaswamy
    Investigational New Drugs, 2014, 32 : 1285 - 1294
  • [2] A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer
    Zhao, Meng
    Pan, Xueliang
    Layman, Rachel
    Lustberg, Maryam B.
    Mrozek, Ewa
    Macrae, Erin R.
    Wesolowski, Robert
    Carothers, Sarah
    Puhalla, Shannon
    Shapiro, Charles L.
    Ramaswamy, Bhuvaneswari
    INVESTIGATIONAL NEW DRUGS, 2014, 32 (06) : 1285 - 1294
  • [3] ADJUVANT TC (DOCETAXEL/CYCLOPHOSPHAMIDE)-HER (TRASTUZUMAB) (TC-HER) IN HER2 POSITIVE BREAST CANCER
    Hara, F.
    Kiyoto, S.
    Takahashi, M.
    Takabatake, D.
    Takashima, S.
    Aogi, K.
    Ohsumi, S.
    BREAST, 2013, 22 : S87 - S87
  • [4] Pertuzumab, Trastuzumab, Docetaxel: a single istitution clinical exeperience for Her2 positive metastatic breast cancer (mBC)
    Martines, C.
    Lavenia, G.
    Salice, P.
    Latteri, F.
    Commendatore, O.
    Sambataro, D.
    Burrafato, G.
    Mattina, M.
    Amadio, P.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] Molecular Mechanisms of Trastuzumab Resistance in HER2 Overexpressing Breast Cancer
    Fiszman, Gabriel L.
    Jasnis, Maria A.
    INTERNATIONAL JOURNAL OF BREAST CANCER, 2011, 2011
  • [6] Radiolabelled Trastuzumab Fab as a theranostic agent for HER2 expressing breast cancer
    Shukla, Jaya
    Rathore, Yogesh
    Kaur, Komalpreet
    Irrinky, Santosh
    Kumar, Rajender
    Bal, Amanjit
    Mittal, Bhagwant R.
    CANCER RESEARCH, 2024, 84 (03)
  • [7] Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer
    Kawajiri, Hidemi
    Takashima, Tsutomu
    Kashiwagi, Shinichiro
    Noda, Satoru
    Onoda, Naoyoshi
    Hirakawa, Kosei
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (01) : 17 - 26
  • [8] Investigation of a combination of trastuzumab and HER2 peptide vaccines for the treatment of breast cancer
    Mittendorf, EA
    Storrer, CE
    Shriver, CD
    Ponniah, S
    Peoples, GE
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (02) : S34 - S34
  • [9] EFFECTS OF TRASTUZUMAB AND LAPATINIB ON HER2 POSITIVE BREAST CANCER TREATMENT
    Jia, W.
    Wang, T. Z.
    JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS, 2019, 33 (02): : 551 - 555
  • [10] Trastuzumab in combination with AT-101 induces cytotoxicity and apoptosis in Her2 positive breast cancer cells
    Bulut, Gulcan
    Atmaca, Harika
    Karaca, Burcak
    FUTURE ONCOLOGY, 2020, 16 (03) : 4485 - 4495
12345